SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 7, 2010
(Exact name of registrant as specified in charter)
Registrants telephone number, including area code: (617) 503-6500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Curis, Inc. (the Company) is hereby furnishing its corporate presentation that it intends to provide to investors and other third parties from time to time as part of its investor relations activities, including in meetings being held in San Francisco from January 11-14, 2010 surrounding the J.P. Morgan 28th Annual Healthcare Conference. A copy of such corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The attached presentation contains statements about the Companys future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both the Companys and its collaborators ability to successfully research, obtain regulatory approvals for, develop and commercialize products based upon the Companys technologies; the Companys ability to obtain and maintain proprietary protection for its technologies and product candidates, including its multi-target inhibitors; competitive pressures; the Companys ability to maintain strategic collaborations, including with Genentech and Debiopharm; the Companys ability to successfully execute on, and receive favorable results from, its proprietary drug development efforts; the Companys ability to raise additional funds to finance its operations; and those factors described in the Companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, and other reports that it files with SEC.
The forward-looking statements included in the attached presentation represent the Companys views as of the date of the attached presentation. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date of the attached presentation.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 and in Exhibit 99.1 attached hereto is being furnished and is not deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) and is not otherwise subject to the liabilities of that section. Accordingly, the information in Exhibit 99.1 attached hereto will not be incorporated by reference into any filing made Registrant under the Securities Act of 1933 or the Exchange Act unless specifically identified therein as being incorporated therein by reference.
See Exhibit Index attached hereto.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.